Cancer News and Research

Latest Cancer News and Research

New critical illness plan from Colonial Life introduced

A new critical illness plan from Colonial Life & Accident Insurance Company can help many working Americans who may be one serious medical issue away from financial problems. Even with good health insurance, a serious illness, such as a heart attack or stroke, could leave employees on the hook for huge expenses.

15 Sep 2009

GENova Biotherapeutics and Bridge Bioresearch sign collaboration agreement

GENova Biotherapeutics Inc. ("GENova") today announced it has signed a collaboration agreement with Bridge Bioresearch Plc. ("Bridge Bioresearch"), an international drug development and discovery company that focuses on metabolic disorders.

15 Sep 2009

New biological process stimulates the growth of blood vessels

Researchers at the University of North Carolina at Chapel Hill School of Medicine and the College of Arts & Sciences have identified a new biological process that spurs the growth of new blood vessels.

15 Sep 2009

Researchers find increased risk of breast cancer in women from the industrial accident zone

People living in the Seveso area of Italy, which was exposed to dioxin after an industrial accident in 1976, have experienced an increased risk of developing cancer. Researchers writing in BioMed Central's open access journal Environmental Health found an increased risk of breast cancer in women from the most exposed zone and an excess of lymphatic and hematopoietic tissue neoplasms in all but the least exposed zone.

15 Sep 2009

Third-quarter fiscal 2009 results announced by DiagnoCure

DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced revenue of $396,468 and a net loss of $4,034,364 or $0.09 per share for the third quarter ending July 31, 2009.

15 Sep 2009

America’s Affordable Health Choices Act helps breast cancer patients recuperate easily

The Breast Cancer Survivor Coalition for Advancement, Reform and Equity (Because we Care) today praised a House of Representatives committee for adopting an amendment to the “America’s Affordable Health Choices Act” (H.R. 3200) that would remove barriers to care for breast cancer survivors.

15 Sep 2009

UCLA receives funds for oral cancer research training

The UCLA School of Dentistry consistently ranks among the country's top dental schools in National Institutes of Health funding. During the past three fiscal years, the school has secured nearly $30 million in grants for oral cancer research and research training. Now, the dental school has received a major infusion of construction funding for the creation of the UCLA Yip Center for Oral/Head & Neck Oncology Research.

15 Sep 2009

Nebulized interferon-gamma helps minimize transmissibility of TB

A new study published in the September 15, 2009, issue of PLoS ONE found that patients with cavitary pulmonary tuberculosis receiving anti-TB medications supplemented with nebulized interferon-gamma have fewer bacilli in the lungs and less inflammation, thereby reducing the transmissibility of tuberculosis in the early phase of treatment.

15 Sep 2009

Breast Preservation Foundation stresses on the importance public health education programs

Amidst the ongoing health-policy debate, Los Angeles surgeon Joel Aronowitz, M.D., founder of the Breast Preservation Foundation, furthered his organization’s health education and quality of care mission by meeting Washington policymakers to discuss how health care reform can help breast cancer patients be informed of all their treatment choices and have access to more advanced techniques like skin-sparing mastectomy.

15 Sep 2009

EGCG in green tea helps prolong preservation of stored blood platelets

In two separate studies, a major component in green tea, epigallocatechin-3-O-gallate (EGCG), has been found to help prolong the preservation of both stored blood platelets and cryopreserved skin tissues.

15 Sep 2009

BioAlliance announces Phase III results of miconazole Lauriad MBT for treatment of oropharyngeal candidiasis

Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that its development partner BioAlliance Pharma SA presented Phase III study results for miconazole Lauriad(R) mucoadhesive buccal tablets (MBT) that demonstrate noninferiority to clotrimazole troches for oropharyngeal candidiasis (OPC), an opportunistic infection of the mouth and throat.

14 Sep 2009

Fair conducted for free skin cancer screening in Louisville

More than 11,000 Americans die each year from skin cancer. Yet when detected early, skin cancer has a cure rate of 99 percent. That's why dermatologists from the American Academy of Dermatology's National Melanoma/Skin Cancer Screening Program conducted free skin cancer screenings at the Kentucky State Fair in Louisville, held Aug. 20-30, 2009.

14 Sep 2009

Vivakor completes third-party validation testing of its VivaBlend nutraceutical product

Vivakor™, Inc. (OTCBB: VIVK) today announced the results of independent, third-party validation testing of its VivaBlend™ nutraceutical product. VivaBlend is a powerful extract developed by the scientists at Vivakor and is derived from over 18 highly bioactive fruits, vegetables and legumes. Through a proprietary formulation and extraction process, Vivakor scientists have maximized the health benefits of VivaBlend by creating an optimum blend of super-antioxidants and powerful plant phenolics and flavonoids.

14 Sep 2009

Aeolus commences second study of AEOL 10150 against Acute Radiation Syndrome

Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced today the initiation of a second study, in mice, to determine the optimal length of treatment with AEOL 10150 when used as a countermeasure to Acute Radiation Syndrome (ARS) in the lungs. This study, led by Zeljko Vujaskovic, M.D. Ph.D. of Duke University, is designed to build on the recently completed study that demonstrated the efficacy of AEOL 10150 as a treatment for damage to the lungs due to exposure to radiation, and determine the most effective duration of delivery for treatment after exposure.

14 Sep 2009

Diabetes drug and chemotherapy kill cancer stem cells in mice

In a one-two punch, a familiar diabetes drug reduced tumors faster and prolonged remission in mice longer than chemotherapy alone by targeting cancer stem cells, Harvard Medical School researchers reported in the September 14 online first edition of Cancer Research, a journal of the American Association for Cancer Research.

14 Sep 2009

Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 2 data of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single agent in the treatment of advanced metastatic renal cell cancer, has been selected for oral presentation at the Eighth International Kidney Cancer Symposium, to be held in Chicago from September 25-26, 2009.

14 Sep 2009

Cytrx initiates tamibarotene and TRISENOX combination dose escalation study

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced the initiation of a dose escalation study with its oncology drug candidate tamibarotene combined with TRISENOX® (arsenic trioxide) injection (marketed by Cephalon, Inc.) in patients with relapsed acute promyelocytic leukemia (APL).

14 Sep 2009

Malnutrition, poor sanitary conditions and HIV leads to defective immune system

The most common causes worldwide include malnutrition, poor sanitary conditions and human immune deficiency virus (HIV) infection. Other causes of temporary or permanent damage to the immune system include old age, medications (e.g. cortisone, cytostatic drugs), radiotherapy, stress after surgery and malignant tumors of the bone marrow and the lymph nodes.

14 Sep 2009

Celldex commences dosing patients in Phase 1/2 study of its CDX-1401 vaccine candidate

Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the first patient has been dosed in a Phase 1/2 study of its vaccine candidate, CDX-1401, in patients with malignant solid tumors that express NY-ESO-1. CDX-1401 is a fully human monoclonal antibody designed to selectively deliver the NY-ESO-1 antigen to dendritic cells to generate a robust immune response against cancer cells expressing NY-ESO-1.

14 Sep 2009

Calypso’s GPS for the Body technology installed at University Of Maryland Greenebaum Cancer Center

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, announced today that the University of Maryland Marlene and Stewart Greenebaum Cancer Center, a National Cancer Institute-designated cancer center in Baltimore, now offers the Calypso® System to provide accurate, precise, real-time tumor tracking for cancer patients undergoing external beam radiation therapy.

14 Sep 2009

Cancer News and Research

Latest Cancer News and Research

New critical illness plan from Colonial Life introduced

GENova Biotherapeutics and Bridge Bioresearch sign collaboration agreement

New biological process stimulates the growth of blood vessels

Researchers find increased risk of breast cancer in women from the industrial accident zone

Third-quarter fiscal 2009 results announced by DiagnoCure

America’s Affordable Health Choices Act helps breast cancer patients recuperate easily

UCLA receives funds for oral cancer research training

Nebulized interferon-gamma helps minimize transmissibility of TB

Breast Preservation Foundation stresses on the importance public health education programs

EGCG in green tea helps prolong preservation of stored blood platelets

BioAlliance announces Phase III results of miconazole Lauriad MBT for treatment of oropharyngeal candidiasis

Fair conducted for free skin cancer screening in Louisville

Vivakor completes third-party validation testing of its VivaBlend nutraceutical product

Aeolus commences second study of AEOL 10150 against Acute Radiation Syndrome

Diabetes drug and chemotherapy kill cancer stem cells in mice

Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium

Cytrx initiates tamibarotene and TRISENOX combination dose escalation study

Malnutrition, poor sanitary conditions and HIV leads to defective immune system

Celldex commences dosing patients in Phase 1/2 study of its CDX-1401 vaccine candidate

Calypso’s GPS for the Body technology installed at University Of Maryland Greenebaum Cancer Center

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Cancer News and Research

Latest Cancer News and Research

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in